Dr. Lisa Marie Digrazia is a pharmacist who is specialized in Oncology in New York, New York. Patients can reach her at 1275 York Ave, New York or contact her on 212-639-8449. Active license number of Dr. Lisa Marie Digrazia is 051.294978 for Oncology in Illinois. Dr. Lisa Marie Digrazia is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Dr. Lisa Marie Digrazia speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Dr. Lisa Marie Digrazia
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Female
Location:
1275 York Ave, New York, New York, 10065-6007
Phone:
212-639-8449
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Lisa Marie Digrazia are as mentioned below.
NPI Number:
1427313543
NPI Enumeration Date:
05 Jul, 2012
NPI Last Update On:
05 Jul, 2012
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Lisa Marie Digrazia are as mentioned below.
Specialization
License Number
State
Status
Oncology
051.294978
Illinois
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1275 York Ave, New York, New York
Zip:
10065-6007
Phone Number:
--
Fax Number:
--
Patients can reach Dr. Lisa Marie Digrazia at 1275 York Ave, New York, New York or can call on phone at 212-639-8449.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.